drugset / Trial / NCT00269724
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to is to evaluate the safety and efficacy of OROS® oxybutynin chloride in patients being treated for urge urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
Timeline
- Start
- 1997-03
- Primary completion
- —
- Completion
- 1997-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxybutynin | Small molecule | 5 mg | Oral |
| Subject | Oxybutynin | Small molecule | 10 mg | Oral |
| Subject | Oxybutynin | Small molecule | 15 mg | Oral |
| Subject | Oxybutynin | Small molecule | 20 mg | Oral |
| Subject | Oxybutynin | Small molecule | 25 mg | Oral |
| Subject | Oxybutynin | Small molecule | 30 mg | Oral |